Lowers the risk of hospitalization for worsening heart failure. Sold as Corlanor. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Ivabradine (sold as Corlanor), first approved Apr 22, 2019, with 0 new uses approved and 0 published complete response letters.
| IVabradine HCl | Part D | $25.2M | +361% | 17,040 |
| Corlanor | Part D | $7.8M | -80% | 3,527 |
| Shortage | Status | First posted | Updated |
|---|---|---|---|
| Ivabradine Solution | To Be Discontinued | Mar 24, 2026 | Mar 24, 2026 |
| Effect of Ivabradine on Adolescent DysautonomiaDysautonomia of Adolescence · Kathryn Armstrong | Phase 2 | Not yet recruiting | Oct 19, 2026 |
| Preoperative Ivabradine Doses for Hemodynamic Stability in FESSHemodynamic Instability · Minia University | Not applicable | Not yet recruiting | Sep 1, 2026 |
| Ivabradine for Heart Rate Reduction During Exercise in Healthy AdultsHealthy Adult · University of British Columbia | Early phase 1 | Recruiting | Jul 21, 2026 |
| Ivabradine in the Acute Management of Cardiogenic ShockCardiogenic Shock Post Myocardial Infarction · National Institute of Cardiovascular Diseases, Pakistan | Phase 3 | Recruiting | Jul 20, 2026 |
| Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery DiseaseCoronary Arterial Disease (CAD), Ischemic Heart Disease (IHD) · Gødstrup Hospital | Phase 2 / Phase 3 | Enrolling by invitation | Dec 5, 2025 |
| Atrial Fibrillation: In Search for the Optimal Target for Rate ControlAtrial Fibrillation (Permanent), Atrial Fibrillation (AF) · The University of Hong Kong | Phase 4 | Not yet recruiting | Aug 22, 2025 |
| Role of Ivabradine for Heart Rate Control in Management of Patients With Sepsis and Septic ShockHeart Rhythm Disorder · Ain Shams University | Not applicable | Not yet recruiting | Dec 19, 2024 |
| Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With SepsisSepsis, Ivabradine · Second Affiliated Hospital of Guangzhou Medical University | Phase 4 | Recruiting | May 31, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA